Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

NCT07446270 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Treatment for Advanced Colorectal Cancer
Treatment for Advanced Pancreatic Cancer

Interventions

DRUG: Colorectal cancer: Tunlametinib + cetuximab β
DRUG: Pancreatic cancer: Tunlametinib + cetuximab β
DRUG: Pancreatic cancer: Tunlametinib +Nimotuzumab

Sponsor

Chinese PLA General Hospital